Compare AbCellera Biologics Inc (ABCL) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Teladoc Health Inc — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Teladoc Health Inc trades at $9.14 (market cap $1.72B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and Teladoc Health Inc is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | TDOC | |
|---|---|---|
Market Cap | $2.35B | $1.72B |
Sector | Health | Health |
52-Week High | $8.12 | $9.52 |
52-Week Low | $2.78 | $4.47 |
Enterprise Value | $1.99B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Teladoc Health (TDOC) trades at $9.52, up 3.48% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company reported Q1 2026 earnings that missed expectations, but revenue remains stable at $2.53 billion for 2025. Recent news highlights expansion through Walmart's platform and ongoing cost-cutting efforts, though BetterHelp segment weakness persists. Analyst consensus is mixed with 33% buy ratings but a price target below current levels at $7.83.
TDOC's recovery story faces headwinds from persistent net losses and negative cash flow, but low P/S ratio of 0.66 offers valuation appeal. Key risks include competitive pressure and execution challenges, while institutional sentiment remains cautious with no sell ratings. The stock's near-term direction hinges on Q2 earnings results and progress toward profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
